LataMed AI Corp.

What they do

The company is developing an AI healthcare analytics platform intended to support clinical decision-making, patient management, and healthcare delivery optimization. Its technologies, still under development and not commercialized, include CardioAI, PulmoAI, and NeuroAI for cardiovascular, pulmonary, and neurological applications. The company also plans a technology-enabled healthcare services coordination model combining digital tools, telehealth, and in-person care, but these services have not been operationalized. Operations are conducted through its wholly-owned Venezuelan subsidiary, Inversiones Long 33, C.A., following a strategic transition in February 2026.

Revenue drivers

• AI Healthcare Platform — Intended to generate revenue through licensing or sale of analytics tools; no revenue to date.
• CardioAI — Cardiovascular risk assessment and analytics module; under development, not commercialized.
• PulmoAI — Pulmonary condition analysis and predictive modeling module; under development, not commercialized.
• NeuroAI — Neurological condition assessment and insights module; under development, not commercialized.

Recent performance

For the six months ended June 30, 2026, the company reported no revenue and a net loss of $140,221, compared to a net loss of $33,783 in the prior-year period. Operating expenses increased to $120,429 from $35,821, driven by higher professional fees. As of June 30, 2026, total assets were $7.8M, with total liabilities of $771,081 and shareholder equity of $7.1M. Cash and equivalents were $0, and operating activities used $83,418 in cash during the period. The company had a working capital deficit of $771,081.

Strategy

Management states it is executing a strategy to develop an AI-enabled digital healthcare platform focused on Latin America. Priorities include integrating and evaluating the intellectual property acquired in the first quarter of 2026, advancing organizational and operational infrastructure, and continuing development of AI-powered clinical decision support, telehealth, patient engagement, and analytics solutions. The company is also engaged in regulatory planning, strategic partnership discussions, and business development initiatives to support future commercialization. The Venezuelan subsidiary is intended to serve as the primary operating platform in Venezuela.

Risks

• Going concern risk — The company has incurred cumulative net losses of $29.7M and lacks sufficient cash to operate for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• No revenue or cash flow — The company has not generated any revenue and generates no cash flow from operations, relying entirely on external financing.
• Development-stage uncertainties — The AI platform and services are under development and not commercialized, with no assurance that they will become commercially viable.
• Dependence on additional financing — The company must secure additional capital through equity or debt offerings; failure to do so could force it to delay or discontinue development activities.

Outlook

Management expects to continue incurring losses and requires additional financing to fund operations. The company plans to seek funding through a private equity offering and may also use debt or equity financing arrangements, but there is no assurance of success. Near-term activities focus on development planning, technology evaluation, and partnership building to support future commercialization in Latin America.